Navigation Links
Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Date:1/31/2008

CALGARY, Jan. 31 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has met the initial criteria to proceed to full enrolment in its U.S. Phase II trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung.

According to the trial protocol, to proceed to full enrolment of 52 patients, Oncolytics had to demonstrate that at least one patient in the first 38 patients treated experienced a complete or partial response, or stable disease for greater than six months. The third patient treated in the study was demonstrated to have stable disease by RECIST criteria for more than six months as measured by CT scan. A PET scan taken at the same time showed that any residual mass was metabolically inert.

A total of 12 patients have received REOLYSIN(R) treatment to date, with five remaining on study. All 12 patients have been treated at the Cancer Therapy and Research Center, University of Texas Health Science Center in San Antonio, Texas (CTRC at UTHSCSA).

"We are very pleased to proceed to the second stage of the REOLYSIN(R) study," said Dr. Monica Mita, Principal Investigator at CTRC at UTHSCSA. "This unique targeted compound has met our expectations so far in terms of both tolerability and efficacy endpoints and we feel it is very important to continue to offer this agent to our patients."

"While still early, these are very encouraging results," said Dr. Karl Mettinger, Chief Medical Officer of Oncolytics. "There are few treatment options for patients with bone or soft tissue cancers, and we are pleased that the trial participants appear to be benefiting from REOLYSIN(R) treatment."

Patients are expected to be enrolled at three additional sites, which include the Montefiore Medical Center/Albert Einstein College of Medicine in the Bronx, New York, the University of Michigan Comprehensive Cancer Center
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
3. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
6. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
7. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
10. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
11. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... , Opinion ... Decade , WASHINGTON, Dec. 9 On Tuesday, December 8, 2009, ... The Decade-2 Education Forum in ... science to America,s students and was sponsored by Amgen , a leading ...
... /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced ... Executive Officer, replacing Dr. Brad Popovich. , "We want to ... over the last four years. Brad has taken the Company ... period of time. Brad has also managed to recruit one ...
... ... Sciences Research Adopts the Genedata Screener® 7.0 Data Management Platform for High Throughput and ... ... a leading provider of advanced software solutions for drug discovery and life science research, ...
Cached Biology Technology:Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 2Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 3Sirius Genomics Announces Change in Leadership 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/12/2014)... 12, 2014 Crossmatch™, a leading provider of ... ® fingerprint readers have been deployed throughout Montparnasse ... Central Mexico . The bakery chain implemented the ... issues caused by employees clocking in for each other. ... readers, Montparnasse relied on paper timecards and a mechanical ...
(Date:11/10/2014)... shelves in early 2010, and people have used them ... be tossed into a washing machine without ever having ... though, has come with risks for young children. , ... found that from 2012 through 2013, U.S. poison control ... years of age swallowing, inhaling, or otherwise being exposed ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... in their own interests and do not cooperate ... severity of infection. The selfish behaviour ... treat antibiotic-resistant infections, according to research being presented ... today. Bacteria work together by using a ...
... TORONTO, ON - Widespread reports of a decline in the ... and speculation that pollination is also likely on the decline. ... long-term evidence of a downward trend in pollination, while also ... numbers may have declined at our research site, but we ...
... San Diego have discovered that a gene critical for programmed ... stem cells, a finding that could help to improve the ... chemotherapy or radiation therapy that kills cancer cells by inducing ... side effects for human cancer patients is the depletion of ...
Cached Biology News:Backstabbing bacteria: A new treatment for infection? 2Biologists find way to reduce stem cell loss during cancer treatment 2
Request Info...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: